Ítem
Solo Metadatos

Clinical efficacy of botulinum toxin type A reconstituted and refrigerated 1 week before its application in external canthus dynamic lines

Mostrar el registro sencillo de la publicación
dc.creatorLizarralde, Mónicaspa
dc.creatorGutiérrez, Sara Helenaspa
dc.creatorVenegas, Adrianaspa
dc.date.accessioned2020-05-26T00:05:55Z
dc.date.available2020-05-26T00:05:55Z
dc.date.created2007-11spa
dc.descriptionBACKGROUND: Allergan Inc. recommends that its botulinum toxin type A (BTX-A; BOTOX) must be refrigerated and applied within 4 hours after its reconstitution to avoid losing its biologic effectiveness. OBJECTIVE: The objective was to compare clinical efficacy in treating external canthus dynamic lines with reconstituted and refrigerated toxin (BTX-A) 1 week before its application versus fresh toxin (BTX-A). METHODS: This study was a double-blind, randomized, clinical trial. A total of 30 patients aged 30 to 60 years having a minimum of one and maximum of six external canthus dynamic lines were treated in one canthus with 15 U of BTX-A reconstituted and refrigerated at 4°C 1 week before being applied and in the other with 15 U of fresh BTX-A. Patients were followed-up on Day 10 and Weeks 6, 12, and 18; assessment included a neuroconduction study of the facial nerve and the investigators' photographic evaluation of the number of external canthus dynamic lines at maximum smile. RESULTS: Outcome measurement did not show statistically significant differences between both groups. CONCLUSION: BTX-A, reconstituted and refrigerated 1 week before its application, has similar clinical efficacy in treating external canthus dynamic lines as does fresh BTX-A. © 2007 by the American Society for Dermatologic Surgery, Inc.spa
dc.description.abstractIntroduction: Central pain is one type of pain that occurs in patients with Parkinson's disease (PD). Because of its low incidence and prevalence, it often goes unnoticed and affected patients do not therefore receive adequate analgesic therapy, which increases their suffering. It is a burning pain with spontaneous onset and periods of exacerbation; pain is poorly localised and usually more intense on the more affected side. Its pathophysiology on patients with PD is not clearly defined. Methods: We performed a search and systematic selection of all clinical studies published from January 1986 to September 2010 concerning central neuropathic pain in Parkinson's disease. Conclusions: Treatment with L-Dopa has not been demonstrated to have an analgesic effect on this type of pain. Future studies are required to improve our understanding of this condition, and to develop interventions for preventing and treating it. © 2011 Sociedad Española de Neurología.spa
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1111/j.1524-4725.2007.33284.x
dc.identifier.doihttps://doi.org/10.1097/00042728-200711000-00005
dc.identifier.issn1076-0512
dc.identifier.issn1524-4725
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/23840
dc.language.isoengspa
dc.relation.citationEndPage1333
dc.relation.citationIssueNo. 11
dc.relation.citationStartPage1328
dc.relation.citationTitleDermatologic Surgery
dc.relation.citationVolumeVol. 33
dc.relation.ispartofDermatologic Surgery, ISSN:1076-0512, 1524-4725, Vol.33, No.11 (2007); pp. 1328-1333spa
dc.relation.urihttps://onlinelibrary.wiley.com/doi/abs/10.1111/j.1524-4725.2007.33284.xspa
dc.relation.urihttps://journals.lww.com/dermatologicsurgery/Abstract/2007/11000/Clinical_Efficacy_of_Botulinum_Toxin_Type_A.5.aspxspa
dc.rights.accesRightsinfo:eu-repo/semantics/closedAccess
dc.rights.accesoBloqueado (Texto referencial)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordBotulinum toxin Aspa
dc.subject.keywordBotulinum toxin Aspa
dc.subject.keywordAdultspa
dc.subject.keywordArticlespa
dc.subject.keywordClinical trialspa
dc.subject.keywordControlled clinical trialspa
dc.subject.keywordControlled studyspa
dc.subject.keywordDouble blind procedurespa
dc.subject.keywordDrug efficacyspa
dc.subject.keywordEyelidspa
dc.subject.keywordFacial nervespa
dc.subject.keywordFemalespa
dc.subject.keywordFollow upspa
dc.subject.keywordFreezingspa
dc.subject.keywordHumanspa
dc.subject.keywordMalespa
dc.subject.keywordNerve conductionspa
dc.subject.keywordPriority journalspa
dc.subject.keywordRandomized controlled trialspa
dc.subject.keywordDilutionspa
dc.subject.keywordDrug potencyspa
dc.subject.keywordDrug stabilityspa
dc.subject.keywordNotespa
dc.subject.keywordAdultspa
dc.subject.keywordBotulinum Toxin Type Aspa
dc.subject.keywordDouble-Blind Methodspa
dc.subject.keywordDrug Administration Schedulespa
dc.subject.keywordDrug Storagespa
dc.subject.keywordFacespa
dc.subject.keywordFemalespa
dc.subject.keywordHumansspa
dc.subject.keywordMalespa
dc.subject.keywordMiddle Agedspa
dc.subject.keywordNeuromuscular Agentsspa
dc.subject.keywordRefrigerationspa
dc.subject.keywordSkin Agingspa
dc.titleClinical efficacy of botulinum toxin type A reconstituted and refrigerated 1 week before its application in external canthus dynamic linesspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos